Clinical, biologic, and virologic features of 18 patients with SLVL and HCV infection
Mean age, y | 58 ± 13.5 |
| Women, % | 78 |
| Mean duration of HCV prior to SLVL, y | 8.5 ± 7.0 |
| Mean duration of HCV prior to MC, y | 7.1 ± 7.7 |
| Mean spleen size, cm | 17.5 ± 2.5 |
| Mean absolute lymphocytosis, × 109/L | 14775 ± 14241 |
| Mean villous lymphocytes, % | 39 ± 22 |
| Mean hemoglobin level, g/dL | 12 ± 1.6 |
| Mean platelet count, × 109/L | 170 ± 61 |
| Normal karyotype, no. | 10/10 |
| Positive B-cell clonality, no. | 14/14 |
| Clinical manifestations of MC, no. | 13 (72%) |
| Skin disease | 10 (55%) |
| Arthralgia | 9 (50%) |
| Peripheral neuropathy | 6 (33%) |
| Renal disease | 4 (22%) |
| Sicca syndrome | 3 (17%) |
| MC type II, no. | 18 (100%) |
| Low C4 level, no. | 13 (72%) |
| Mode of HCV contamination (n = 18) | |
| Blood transfusion | 11 (61%) |
| IVDU | 1 (6%) |
| Unknown | 6 (33%) |
| HCV genotype (n = 13) | |
| 1 | 7 (54%) |
| 2 | 4 (22%) |
| 3 | 1 (7.7%) |
| 4 | 1 (7.7%) |
| Mean ALT level, × ULN | 2.4 ± 1.4 |
| Liver histology (Metavir score)*(n = 15) | |
| Activity (0-3) | 1.5 ± 1.0 |
| Fibrosis (0-4) | 1.0 ± 1.4 |
| Cirrhosis | 3 (20%) |
Mean age, y | 58 ± 13.5 |
| Women, % | 78 |
| Mean duration of HCV prior to SLVL, y | 8.5 ± 7.0 |
| Mean duration of HCV prior to MC, y | 7.1 ± 7.7 |
| Mean spleen size, cm | 17.5 ± 2.5 |
| Mean absolute lymphocytosis, × 109/L | 14775 ± 14241 |
| Mean villous lymphocytes, % | 39 ± 22 |
| Mean hemoglobin level, g/dL | 12 ± 1.6 |
| Mean platelet count, × 109/L | 170 ± 61 |
| Normal karyotype, no. | 10/10 |
| Positive B-cell clonality, no. | 14/14 |
| Clinical manifestations of MC, no. | 13 (72%) |
| Skin disease | 10 (55%) |
| Arthralgia | 9 (50%) |
| Peripheral neuropathy | 6 (33%) |
| Renal disease | 4 (22%) |
| Sicca syndrome | 3 (17%) |
| MC type II, no. | 18 (100%) |
| Low C4 level, no. | 13 (72%) |
| Mode of HCV contamination (n = 18) | |
| Blood transfusion | 11 (61%) |
| IVDU | 1 (6%) |
| Unknown | 6 (33%) |
| HCV genotype (n = 13) | |
| 1 | 7 (54%) |
| 2 | 4 (22%) |
| 3 | 1 (7.7%) |
| 4 | 1 (7.7%) |
| Mean ALT level, × ULN | 2.4 ± 1.4 |
| Liver histology (Metavir score)*(n = 15) | |
| Activity (0-3) | 1.5 ± 1.0 |
| Fibrosis (0-4) | 1.0 ± 1.4 |
| Cirrhosis | 3 (20%) |
IVDU indicates intravenous drug user; ALT, alanine aminotransferase; ULN, times the upper limit of normal values.
Metavir score: liver biopsy specimens were evaluated according to previously validated scoring system, graded on a scale of 0 to 3 for the inflammatory activity (A0-A3), and of 0 to 4 for the fibrosis (F0-F4).